(19)
(11) EP 0 731 165 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
10.08.2005 Bulletin 2005/32

(45) Mention of the grant of the patent:
15.06.2005 Bulletin 2005/24

(21) Application number: 96200578.1

(22) Date of filing: 04.03.1996
(51) International Patent Classification (IPC)7: C12N 15/10, C07K 14/155, G01N 33/569

(54)

Human T-cell line infected with HIV-2 which secretes functionally intact HIV-2 GP160

Mit HIV-2 infizierte menschliche T-Zelllinie die funktionell intaktes HIV-2 gp160 sekretiert

Lignée de lymphocytes-T humaine, infectée par le HIV-2 sécrétant une HIV-2 gp160 fonctionellement intacte

(84) Designated Contracting States:
AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

(30) Priority: 07.03.1995 US 402481

(43) Date of publication of application:
11.09.1996 Bulletin 1996/37

(73) Proprietor: bioMérieux, Inc.
Durham, NC 27712 (US)

(72) Inventors:
  • Sarngadharan, Mangalasseril Gopalan
    McLean, VA 22101 (US)
  • Kalyanaraman, Vaniambadi Srinivasan
    Germantown, MD 20874 (US)
  • Larue Kalisz, Irene
    Frederick, MD 21704 (US)

(74) Representative: Prins, Hendrik Willem et al
Arnold & Siedsma, Advocaten en Octrooigemachtigden, Sweelinckplein 1
2517 GK Den Haag
2517 GK Den Haag (NL)


(56) References cited: : 
WO-A-89/06276
US-A- 5 122 468
 US-A- 5 116 740
   
       
    Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).